Sodium Benzoate Therapy for Anti-NMDAR Encephalitis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, including immunotherapy and antipsychotic drugs, are often ineffective, and there is a need for a more effective prophylaxis or treatment for this autoimmune encephalitis.

Innovation Solution

A pharmaceutical composition comprising an effective amount of sodium benzoate, administered orally, is used to inhibit D-amino acid oxidase activity, thereby enhancing NMDA receptor function and treating anti-NMDAR encephalitis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immunotherapy and antipsychotic drugs are used to treat anti-NMDAR encephalitis, then treatment coverage is provided, but treatment effectiveness is insufficient

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment coverage

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the biochemical parameter of D-serine availability by administering D-cycloserine (a DAAO inhibitor) and D-serine supplements, shifting the therapeutic approach from immune modulation to direct NMDA receptor function enhancement, thereby improving treatment effectiveness for refractory patients

Inventive Principle:

Principle #35Parameter changes

2Reliability

If D-amino acid oxidase activity is high, then D-serine degradation increases, but NMDA receptor function decreases

Engineering Contradiction:

ImproveNMDA receptor functionVSAvoidD-serine

Core Design Contradiction:

ReliabilityVSLoss of substance

Solution Approach 1:

The patent converts the harmful effect of high DAAO activity (which degrades D-serine and reduces NMDA receptor function) into a benefit by using DAAO inhibitors (D-cycloserine) to block this degradation pathway, thereby preserving and enhancing D-serine levels and NMDA receptor activation in anti-NMDAR encephalitis patients

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces D-cycloserine as an intermediary substance that inhibits DAAO enzyme activity, preventing the conversion of D-serine to harmful byproducts and allowing D-serine to accumulate and activate NMDA receptors effectively

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Sodium benzoate effectively prevents or treats anti-NMDAR encephalitis by enhancing NMDA receptor function, reducing symptoms such as psychosis and neurologic dysfunction, and providing an alternative to refractory therapies.

Implementation Method 1

sodium benzoate may be administered to the subject in an amount ranging from 200 mg/day to 2000 mg/day... sodium benzoate can induce antipsychotic effect... sodium benzoate effectively prevents or treats anti-NMDAR encephalitis by enhancing NMDA receptor function

Methodology Applied

Scientific EffectEnzyme inhibition: Enzyme

Data Source

PatentEP3823609B1Sodium benzoate for use in preventing or treating Anti-n-methyl-d-aspartate receptor encephalitis

Publication Date: 2026.03.04 EXCELSIOR PHARMATECH LABS

AI summary

The present disclosure provides a method of preventing or treating anti-NMDAR encephalitis in a subject in need thereof, including administering to the subject an effective amount of benzoic acid or a salt and derivative thereof.